07-01-2021
Tada Images / Shutterstock.com
Pharmaceutical companies MSD (known as 'Merck & Co' in the US) and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia (ezetimibe) should be reversed because the circumstances of the class members do not justify an award of class status.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
MSD, Glenmark, generic competition, pay-for-delay, Zetia, cholesterol drug, ezetimibe, class certification, settlement, wholesalers, patent infringement
Virginia judge says court should deny class cert in Zetia antitrust suit
27-01-2022
Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case
04-11-2021
Buyers of Zetia seek class recertification after 4th circ ruling
28-09-2021
Glenmark becomes fifth generic to be charged with US antitrust violations
02-07-2020
Par avoids pay-for-delay suit after court accepts payment was ‘fair’
10-03-2020
